Search research articles
Contact Us
Filters
Showing results (371-380 of 483) with videos related to
Page
of 49
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2009
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
José Baselga, Vladimir Semiglazov, Peter van Dam, et al.
The Lancet. Oncology
|
August 23, 2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Michael Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth, et al.
Oncoimmunology
|
September 14, 2020
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)
Carl Christoph Schimanski, Stefan Kasper, Susanna Hegewisch-Becker, et al.
Cells
|
December 24, 2021
Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles
Heide-Marie Binder, Nicole Maeding, Martin Wolf, et al.
Annals of Hematology
|
May 12, 2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Breast (Edinburgh, Scotland)
|
November 6, 2025
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34
Stephanie Kacerovsky-Strobl, Christine Deutschmann, Dominik Hlauschek, et al.
Leukemia & Lymphoma
|
September 27, 2019
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
Heinz Ludwig, Wolfram Pönisch, Stefan Knop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2010
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial
Hans Theodor Eich, Volker Diehl, Helen Görgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2026
Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial
James M Cleary, Christoph Springfeld, Dirk Arnold, et al.
The New England Journal of Medicine
|
February 14, 2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
Michael Gnant, Brigitte Mlineritsch, Walter Schippinger, et al.
Page
of 49
Search research articles
Search
Showing results (371-380 of 483) with videos related to
Sort By:
Page
of 49
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2009
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
José Baselga, Vladimir Semiglazov, Peter van Dam, et al.
The Lancet. Oncology
|
August 23, 2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Michael Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth, et al.
Oncoimmunology
|
September 14, 2020
Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)
Carl Christoph Schimanski, Stefan Kasper, Susanna Hegewisch-Becker, et al.
Cells
|
December 24, 2021
Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles
Heide-Marie Binder, Nicole Maeding, Martin Wolf, et al.
Annals of Hematology
|
May 12, 2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Breast (Edinburgh, Scotland)
|
November 6, 2025
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34
Stephanie Kacerovsky-Strobl, Christine Deutschmann, Dominik Hlauschek, et al.
Leukemia & Lymphoma
|
September 27, 2019
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
Heinz Ludwig, Wolfram Pönisch, Stefan Knop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2010
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial
Hans Theodor Eich, Volker Diehl, Helen Görgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 2026
Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial
James M Cleary, Christoph Springfeld, Dirk Arnold, et al.
The New England Journal of Medicine
|
February 14, 2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer
Michael Gnant, Brigitte Mlineritsch, Walter Schippinger, et al.
Page
of 49